Developer docs
API playgroundTry for free, no card

Search company profiles

Sagent Pharmaceuticals

Full company profile

uuid0008ps2

Namestring
Sagent Pharmaceuticals
Legal namestring
Sagent Pharmaceuticals
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Sagent Pharmaceuticals is a U.S.-headquartered specialty pharmaceutical company focused on developing, manufacturing, sourcing, and marketing generic injectable products. The company was founded in 2007 and is based in Schaumburg, Illinois, with an India operations hub in Hyderabad supporting regional management, business development, and back-office functions. Its portfolio spans multiple therapeutic categories and is offered in multiple packaging configurations — vials, prefilled syringes, and premixed bags — including a dedicated Ready-to-Use line and products acquired through the Athenex and Omega Laboratories transactions. Across the entire portfolio, Sagent applies its proprietary PreventIV Measures® Packaging and Labeling system, a registered trademark designed to reduce medication errors through prominent name/strength display and design choices that mitigate optical illusions and color-reading ambiguity.

The company sells to hospitals, healthcare systems, and pharmaceutical wholesalers using a B2B sales-led go-to-market model: a direct online ordering portal (order.sagentpharma.com), a customer service number (1-866-625-1618), and a U.S. regional sales contact network. Pricing is quote-based and not publicly disclosed; revenue is generated through one-time product transactions rather than subscriptions or licensing. Recent strategic activity — the 2025 Provepharm partnership for Bludigo® (an FDA-approved diagnostic dye injection entering a $200M+ U.S. market), the Athenex injectable acquisition, and the January 2025 promotion of a VP of Business Development & Growth Strategy — signals incremental expansion of the product surface into urology/diagnostic dyes and active inorganic portfolio building. The company is led by CEO Vishy Chebrol, with CFO Jeff Greve, EVP Commercial Operations Don Bullock, Head of India Operations Prakash Baliga, and VP Business Development & Growth Strategy Jyothi Chaluvadi.

Short descriptiontext

Sagent Pharmaceuticals is a Schaumburg, Illinois-based generic injectable pharmaceuticals manufacturer founded in 2007, selling to U.S. hospitals, healthcare systems, and wholesalers via direct sales and an online ordering portal, with its portfolio differentiated by the proprietary PreventIV Measures® safety-focused packaging and labeling system.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSchaumburg, United States
HQ citystring
Schaumburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic injectables, pharmaceutical manufacturing, injectable pharmaceuticals, hospital drug supply, diagnostic dyes
Industry1 code
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Injectable Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceuticals Sales
TypeOne Time License
Description

Sagent generates revenue through the sale of generic injectable pharmaceuticals across multiple therapeutic categories. Products are sold in various packaging configurations including vials, syringes, and premix bags to healthcare providers, hospitals, and wholesalers. Revenue is derived from one-time product transactions.

sagentpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1PreventIV Measures
Description

Sagent's comprehensive user-driven, patient-centered approach to labeling and packaging designed to help prevent medication errors.

sagentpharma.com
+2 more records
Core offering1 text field

Sagent Pharmaceuticals develops, manufactures, sources, and markets generic injectable pharmaceuticals spanning multiple therapeutic categories. Products are sold in vials, syringes, and premix bag configurations to hospitals, healthcare systems, and pharmaceutical wholesalers, differentiated by the company's proprietary PreventIV Measures® patient-safety packaging and labeling system.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sagent Pharmaceuticals is a leading provider of generic injectable pharmaceuticals organized as a unified portfolio. The core offering consists of generic pharmaceuticals spanning multiple therapeutic categories, available in vials, syringes, and premix bags. The portfolio includes specialty sub-brands like Bludigo.com (indigo carmine diagnostic injection) and Glydo.com, acquired products from Athenex, and Ready-to-Use formulations. All products feature the PreventIV Measures® Packaging and Labeling system as a differentiating quality enhancement to help reduce medication errors.

Product and service1 record
1Generic Injectable Pharmaceuticals
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-12-03
Description

Sagent Pharmaceuticals entered a strategic partnership with Provepharm to commercialize diagnostic dyes in the U.S. market. The partnership launched with Bludigo® (indigotindisulfonate sodium), an FDA-approved indigo carmine injection, enabling Sagent to enter the U.S. diagnostic dye market valued at over $200 million and expand into the urology space. The partnership aligns with Provepharm's shift toward innovative dyes for surgical use, particularly fluorescence-guided surgery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fresenius Kabi is one of the largest global manufacturers of generic injectable pharmaceuticals, supplying hospitals across multiple therapeutic categories in vials, syringes, and premix formats — directly comparable to Sagent's core offering and channel.

TypeDirect peer
Description

Hikma is a leading generic injectable manufacturer with a U.S. hospital-focused franchise spanning multiple therapeutic classes and packaging configurations, making it a close operating peer to Sagent Pharmaceuticals.

TypeBroad incumbent
Description

Through its acquisition of Hospira, Pfizer operates the largest generic injectable portfolio in the U.S. hospital market, directly overlapping with Sagent's hospital injectable focus but from a much broader diversified pharma footprint.

TypeDirect peer
Description

Dr. Reddy's operates a sizable North American generic injectable business with broad therapeutic coverage and a strong manufacturing base in India, comparable to Sagent's U.S./India operating model.

TypeDirect peer
Description

Aurobindo is a major Indian-headquartered generics manufacturer with an injectable franchise supplying U.S. hospitals, closely aligned with Sagent on therapeutic breadth, channels, and India-led cost structure.

TypeDirect peer
Description

Gland Pharma is an India-based specialist in generic injectables with deep U.S. hospital relationships — directly comparable to Sagent and notably connected through the prior background of Sagent's VP of Business Development & Growth Strategy.

TypeDirect peer
Description

Amneal operates a U.S. generics franchise with growing injectables and specialty sterile injectable offerings, overlapping with Sagent on product type, channels, and customer base.

TypeBroad incumbent
Description

Teva is one of the world's largest generic manufacturers with an injectable offering aimed at U.S. hospitals; it competes broadly with Sagent across therapeutic categories but from a vastly larger, more diversified portfolio.

TypeDirect peer
Description

Lannett is a U.S. generic drug manufacturer with a portfolio that includes injectable products sold through similar B2B channels to hospitals, wholesalers, and GPOs — making it a relevant smaller-scale operating peer to Sagent.

TypeEmerging player
Description

Provepharm is Sagent's strategic partner for the U.S. launch of Bludigo® and is developing innovative dyes for surgical use, particularly fluorescence-guided surgery — an emerging specialty pharmaceutical company operating in adjacent therapeutic territory to Sagent's hospital channel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sagent Pharmaceuticals

Generic Injectable Pharmaceuticalssagentpharma.com

Sagent Pharmaceuticals is a Schaumburg, Illinois-based generic injectable pharmaceuticals manufacturer founded in 2007, selling to U.S. hospitals, healthcare systems, and wholesalers via direct sales and an online ordering portal, with its portfolio differentiated by the proprietary PreventIV Measures® safety-focused packaging and labeling system.

What Sagent Pharmaceuticals does

Sagent Pharmaceuticals is a U.S.-headquartered specialty pharmaceutical company focused on developing, manufacturing, sourcing, and marketing generic injectable products. The company was founded in 2007 and is based in Schaumburg, Illinois, with an India operations hub in Hyderabad supporting regional management, business development, and back-office functions. Its portfolio spans multiple therapeutic categories and is offered in multiple packaging configurations — vials, prefilled syringes, and premixed bags — including a dedicated Ready-to-Use line and products acquired through the Athenex and Omega Laboratories transactions. Across the entire portfolio, Sagent applies its proprietary PreventIV Measures® Packaging and Labeling system, a registered trademark designed to reduce medication errors through prominent name/strength display and design choices that mitigate optical illusions and color-reading ambiguity.

The company sells to hospitals, healthcare systems, and pharmaceutical wholesalers using a B2B sales-led go-to-market model: a direct online ordering portal (order.sagentpharma.com), a customer service number (1-866-625-1618), and a U.S. regional sales contact network. Pricing is quote-based and not publicly disclosed; revenue is generated through one-time product transactions rather than subscriptions or licensing. Recent strategic activity — the 2025 Provepharm partnership for Bludigo® (an FDA-approved diagnostic dye injection entering a $200M+ U.S. market), the Athenex injectable acquisition, and the January 2025 promotion of a VP of Business Development & Growth Strategy — signals incremental expansion of the product surface into urology/diagnostic dyes and active inorganic portfolio building. The company is led by CEO Vishy Chebrol, with CFO Jeff Greve, EVP Commercial Operations Don Bullock, Head of India Operations Prakash Baliga, and VP Business Development & Growth Strategy Jyothi Chaluvadi.

Sagent Pharmaceuticals firmographics

Firmographics
Name
Sagent Pharmaceuticals
Legal name
Sagent Pharmaceuticals
Website
https://sagentpharma.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Short description
Sagent Pharmaceuticals is a Schaumburg, Illinois-based generic injectable pharmaceuticals manufacturer founded in 2007, selling to U.S. hospitals, healthcare systems, and wholesalers via direct sales and an online ordering portal, with its portfolio differentiated by the proprietary PreventIV Measures® safety-focused packaging and labeling system.
Ownership category
akta.pro rank

Sagent Pharmaceuticals industry classification

Industry
Product category
Generic Injectable Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products

Keywords

  • Generic injectables
  • Pharmaceutical manufacturing
  • Injectable pharmaceuticals
  • Hospital drug supply
  • Diagnostic dyes

Where Sagent Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Schaumburg
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Sagent Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Generic Pharmaceuticals Sales: Sagent generates revenue through the sale of generic injectable pharmaceuticals across multiple therapeutic categories. Products are sold in various packaging configurations including vials, syringes, and premix bags to healthcare providers, hospitals, and wholesalers. Revenue is derived from one-time product transactions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Sagent Pharmaceuticals product offering

Product offering

Core offering

Sagent Pharmaceuticals develops, manufactures, sources, and markets generic injectable pharmaceuticals spanning multiple therapeutic categories. Products are sold in vials, syringes, and premix bag configurations to hospitals, healthcare systems, and pharmaceutical wholesalers, differentiated by the company's proprietary PreventIV Measures® patient-safety packaging and labeling system.

Product overview

Sagent Pharmaceuticals is a leading provider of generic injectable pharmaceuticals organized as a unified portfolio. The core offering consists of generic pharmaceuticals spanning multiple therapeutic categories, available in vials, syringes, and premix bags. The portfolio includes specialty sub-brands like Bludigo.com (indigo carmine diagnostic injection) and Glydo.com, acquired products from Athenex, and Ready-to-Use formulations. All products feature the PreventIV Measures® Packaging and Labeling system as a differentiating quality enhancement to help reduce medication errors.

Differentiator

Problem solved

Functional benefit

Brands

  • PreventIV Measures: Sagent's comprehensive user-driven, patient-centered approach to labeling and packaging designed to help prevent medication errors.
  • Glydo
  • Bludigo

Products and services

  • Generic Injectable Pharmaceuticals

Companies that use Sagent Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Sagent Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Sagent Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ProvepharmcoreGTM or Marketing Partner · 3 December 2025Sagent Pharmaceuticals entered a strategic partnership with Provepharm to commercialize diagnostic dyes in the U.S. market. The partnership launched with Bludigo® (indigotindisulfonate sodium), an FDA-approved indigo carmine injection, enabling Sagent to enter the U.S. diagnostic dye market valued at over $200 million and expand into the urology space. The partnership aligns with Provepharm's shift toward innovative dyes for surgical use, particularly fluorescence-guided surgery.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Sagent Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Fresenius Kabi: Fresenius Kabi is one of the largest global manufacturers of generic injectable pharmaceuticals, supplying hospitals across multiple therapeutic categories in vials, syringes, and premix formats — directly comparable to Sagent's core offering and channel.
  • Hikma Pharmaceuticals: Hikma is a leading generic injectable manufacturer with a U.S. hospital-focused franchise spanning multiple therapeutic classes and packaging configurations, making it a close operating peer to Sagent Pharmaceuticals.
  • Dr. Reddy's Laboratories: Dr. Reddy's operates a sizable North American generic injectable business with broad therapeutic coverage and a strong manufacturing base in India, comparable to Sagent's U.S./India operating model.
  • Aurobindo Pharma: Aurobindo is a major Indian-headquartered generics manufacturer with an injectable franchise supplying U.S. hospitals, closely aligned with Sagent on therapeutic breadth, channels, and India-led cost structure.
  • Gland Pharma: Gland Pharma is an India-based specialist in generic injectables with deep U.S. hospital relationships — directly comparable to Sagent and notably connected through the prior background of Sagent's VP of Business Development & Growth Strategy.
  • Amneal Pharmaceuticals: Amneal operates a U.S. generics franchise with growing injectables and specialty sterile injectable offerings, overlapping with Sagent on product type, channels, and customer base.
  • Lannett: Lannett is a U.S. generic drug manufacturer with a portfolio that includes injectable products sold through similar B2B channels to hospitals, wholesalers, and GPOs — making it a relevant smaller-scale operating peer to Sagent.

Broad incumbents

  • Pfizer (Hospital Injectables / Hospira): Through its acquisition of Hospira, Pfizer operates the largest generic injectable portfolio in the U.S. hospital market, directly overlapping with Sagent's hospital injectable focus but from a much broader diversified pharma footprint.
  • Teva Pharmaceutical Industries: Teva is one of the world's largest generic manufacturers with an injectable offering aimed at U.S. hospitals; it competes broadly with Sagent across therapeutic categories but from a vastly larger, more diversified portfolio.

Emerging players

  • Provepharm: Provepharm is Sagent's strategic partner for the U.S. launch of Bludigo® and is developing innovative dyes for surgical use, particularly fluorescence-guided surgery — an emerging specialty pharmaceutical company operating in adjacent therapeutic territory to Sagent's hospital channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Sagent Pharmaceuticals social profiles

Digital presence

Sagent Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sagent Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Sagent Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sagent Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sagent Pharmaceuticals

What does Sagent Pharmaceuticals do?

Sagent Pharmaceuticals develops, manufactures, sources, and markets generic injectable pharmaceuticals spanning multiple therapeutic categories. Products are sold in vials, syringes, and premix bag configurations to hospitals, healthcare systems, and pharmaceutical wholesalers, differentiated by the company's proprietary PreventIV Measures® patient-safety packaging and labeling system.

Is Sagent Pharmaceuticals a public or private company?

Sagent Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sagent Pharmaceuticals founded?

Sagent Pharmaceuticals was founded in 2006. It employs 101 to 250 people.

Where is Sagent Pharmaceuticals based?

Sagent Pharmaceuticals is headquartered in Schaumburg, United States, in the North America region.

How does Sagent Pharmaceuticals make money?

One revenue line is on record: generic Pharmaceuticals Sales.

Who are Sagent Pharmaceuticals's main competitors?

Direct peers on record are Fresenius Kabi, Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Aurobindo Pharma, Gland Pharma, Amneal Pharmaceuticals and Lannett. Broad incumbents are Pfizer (Hospital Injectables / Hospira) and Teva Pharmaceutical Industries. Provepharm is listed as an emerging player.

Does Sagent Pharmaceuticals have an API?

No public API is recorded for Sagent Pharmaceuticals.

What industry is Sagent Pharmaceuticals in?

Sagent Pharmaceuticals's product category is Generic Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSagent Pharmaceuticals Launches Zyogreen®, the First and Only Ready-to-Use Indocyanine Green Injection in the U.S.Sagent Pharmaceuticals launched Zyogreen, the first FDA-approved ready-to-use indocyanine green injection in the U.S., commercially available under a Provepharm partnership. The U.S. ICG market was about $128 million for the twelve months ended July 2026. The product is indicated for fluorescence imaging in vascular, gastrointestinal, and other procedures.PR NewswireSagent Pharmaceuticals Launches Zyogreen®, the First and Only Ready-to-Use Indocyanine Green Injection in the U.S.Sagent Pharmaceuticals launched Zyogreen, the first FDA-approved ready-to-use indocyanine green injection in the U.S., commercially available. The U.S. ICG market was about $128 million for the twelve months ended July 2026. The product is distributed nationwide under a Provepharm partnership.openPR.comEmerging Sub-Segments Transforming the Alkylating Agents Market LandscapeThe alkylating agents market is projected to reach $6.9 billion by 2030, growing at a compound annual growth rate of 5.2%, driven by increased oncology demand, aging populations, and expanding cancer screening programs. In June 2024, Dr. Reddy's Laboratories partnered with Ingenus Pharmaceuticals to commercialize Cyclophosphamide injection for the US oncology market, while Avenacy Inc. launched Melphalan Hydrochloride in January 2024 as a generic equivalent to Alkeran for Injection.HrtodayJyothi Chaluvadi Appointed as VP – Business Development & Growth Strategy at Sagent PharmaceuticalsSagent Pharmaceuticals announced the appointment of Jyothi Chaluvadi as Vice President – Business Development & Growth Strategy, based in Hyderabad. Chaluvadi will lead the company's global growth agenda, portfolio strategy, licensing initiatives, and strategic partnerships across regulated markets. Prior to this promotion, she served as Senior Director – Business Development & Growth Strategy at Sagent and currently holds the role of Head of Business Development at GCBC Vaccines Private Limited, with extensive prior experience at Gland Pharma.Eyes On EyecareSagent launches travoprost 0.004% generic for IOP reductionSagent Pharmaceuticals launched travoprost 0.004% ophthalmic solution in the U.S., its first ophthalmic product. The generic of Novartis's TRAVATAN Z treats open-angle glaucoma by reducing intraocular pressure, with one drop once daily. Safety warnings include iris pigmentation and macular edema, and adverse reactions include ocular hyperemia in 30-50% of patients.PR NewswireSagent Announces Launch of Travoprost Ophthalmic Solution, USPSagent Pharmaceuticals launched Travoprost Ophthalmic Solution, USP 0.004%, for open-angle glaucoma or ocular hypertension. The product targets a $61 million market in the 12 months ended July 2025, with more products planned. The combined ophthalmic market is expected to exceed $8.6 billion.TracxnTop Companies in Generic Injectables (Jul, 2025)The article presents a ranked list of top generic injectables startups, highlighting ImprimisRx, Sagent Pharma, Exela Pharma, and Zenotech Laboratories along with their key operational and financial metrics. It notes that these entities have received varying levels of funding, with Sagent Pharma having raised the most at $153M, while others like ImprimisRx and Exela Pharma have secured smaller amounts or are in earlier stages. The report also mentions that several of these companies were founded by alumni from institutions such as BITS Pilani, Columbia Business School, and IIM Bangalore.The Times of Indiagland pharma: Kedaara, TA Associates vie for minority stake in Sagent Pharma - The Economic TimesPrivate equity firms Kedaara Capital and TA Associates are in talks to acquire a significant minority stake in US-based Sagent Pharma, owned by former Gland Pharma promoter Ravi Penmetsa, at a valuation of $500-600 million with a planned investment of $150-200 million. Investment bank Rothschild is advising Sagent on the fundraising plan. Sagent Pharma, founded in 2006 in Illinois, specializes in generic injectables for the US market and was acquired by Penmetsa-controlled Ellimist Singapore from Japan's Nichi-Iko in 2023.PR NewswireSagent Pharmaceuticals Issues Voluntary Nationwide Recall of Docetaxel Injection, USP Due to Potential Presence of Particulate MatterSagent Pharmaceuticals announced a voluntary nationwide recall of two lots of Docetaxel Injection, USP (80 mg/8 mL and 160 mg/16 mL multi-dose vials) distributed between October 11, 2023, and April 11, 2024. The recall was initiated following a customer complaint about potential particulate matter from the stopper in the drug product, which poses serious health risks including inflammation of a vein, granuloma, and potentially life-threatening blood clot events if administered intravenously. No adverse events have been reported to date, and customers are being notified to quarantine and return the affected products.FiercePharmaSagent Pharmaceuticals recalls injectable seizure med thanks to familiar packaging glitchSagent Pharmaceuticals is recalling four lots of injectable levetiracetam due to lack of container closure integrity, which could cause loss of sterility and serious infections. The company has not received any side effect reports linked to the suspect lots. The batches were shipped between March and November this year.